- Abivax (ABVX, Financial) confirms the completion of Phase 3 ABTECT trial enrollment in Q2 2025.
- Top-line induction results are anticipated in Q3 2025.
- Executive team invests in 120,000 shares, indicating confidence in the company's future.
Abivax S.A. (ABVX), a leading clinical-stage biotechnology company, has scheduled its Annual General Meeting for June 6, 2025, in Paris, France. The company has provided updates on its significant operational milestones, particularly the progress of its Phase 3 ABTECT clinical program, which is on track for completion.
The ABTECT trials, pivotal for Abivax's therapeutic development for chronic inflammatory diseases, are proceeding as planned. Enrollment for the induction trials is expected to conclude in the second quarter of 2025, with top-line induction results set to be released in the third quarter of the same year. These results are crucial for validating the company's innovative approach to stabilizing immune response.
In a demonstration of confidence, Abivax's executive leadership, including CEO Marc de Garidel, has invested in approximately 120,000 ordinary shares during the first quarter of 2025. This investment, valued at around $747,600 at the current share price of $6.23, underscores the leadership's optimism about the company's trajectory and alignment with its shareholders.
With a market capitalization of $380.5 million, Abivax views 2025 as a potentially transformative year, anticipating major clinical readouts that could significantly impact its valuation. The company is committed to maintaining its operational momentum as it approaches these critical milestones.
